What is Zacks Research’s Estimate for ORMP Q2 Earnings?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Zacks Research issued their Q2 2026 earnings estimates for Oramed Pharmaceuticals in a research note issued to investors on Monday, June 8th. Zacks Research analyst M. Marin anticipates that the biotechnology company will post earnings of $0.15 per share for the quarter. Zacks Research also issued estimates for Oramed Pharmaceuticals’ Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.24 EPS and FY2026 earnings at $0.71 EPS.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its earnings results on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02.

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research report on Friday, March 27th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Oramed Pharmaceuticals Trading Up 1.4%

Shares of ORMP opened at $3.70 on Thursday. The stock has a market cap of $151.43 million, a P/E ratio of 1.43 and a beta of 1.26. The company has a 50-day moving average of $3.90 and a two-hundred day moving average of $3.46. Oramed Pharmaceuticals has a 12-month low of $1.98 and a 12-month high of $5.01.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its position in shares of Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 3,909 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Oramed Pharmaceuticals in the first quarter valued at approximately $63,000. Dimensional Fund Advisors LP raised its position in shares of Oramed Pharmaceuticals by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 7,738 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new stake in Oramed Pharmaceuticals in the first quarter valued at approximately $331,000. Finally, Kathmere Capital Management LLC purchased a new stake in Oramed Pharmaceuticals in the first quarter valued at approximately $51,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.